Navigation Links
Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer
Date:5/30/2008

Woodcliff Lake, N.J., May 15, 2008The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.

The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy, said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine.

About Study 211 Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients received a median of four cycles of eribulin mesylate (range 1-27). No premedication to prevent hypersensitivity was required.

Two-hundred sixty-n
'/>"/>

Contact: Judee Shuler
201-746-2241
Eisai Inc.
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UM coral scientist Peter Glynn wins award for scholarly activity
2. Blood pressure drug telmisartan shows powerful activity against stroke
3. Cold Spring Harbor Protocols highlights a method that captures cell growth and activity
4. CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients
5. Cell-based therapy shows promise in patients with Parkinsons disease
6. Scientists test device to track medication adherence in patients with HIV/AIDS
7. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
8. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
9. Pregnant patients lose out in breast cancer treatment; a new approach is needed
10. Mental stress reduces blood flow to the heart in patients with gene variation
11. 2 new therapies show promise for cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 According to ... Solutions (Hardware, Software, Services), by Applications (Surveillance (Airborne, ... by End-Users (Military & Defense & Commercial) - ... Imaging Market is expected to grow from $7252.0 ... at a Compound Annual Growth Rate (CAGR) of ...
(Date:5/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... owned subsidiary, 3D-ID LLC, a company engaged in biometric ... the biometrics technology portion of the recently awarded TIES ... Department of the Army. 3D-ID LLC has ... government, law enforcement and security agencies. ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... C deficiency during pregnancy can have serious consequences for the ... be reversed by vitamin C supplements after birth. This is ... published in the scientific journal PLOS ONE . ... adults in the developed world suffer from vitamin C deficiency. ...
... can have serious consequences for the foetal brain. And once ... C supplements after birth. This is shown through new research ... journal PLOS ONE . Population studies show that ... world suffer from vitamin C deficiency. Therefore, pregnant women should ...
... -- An international scientific collaboration that includes two Kansas ... it comes to potential animal and human health advancements, ... pig. The sequenced genome gives researchers a genetic ... of DNA and genes that give pigs their traits ...
Cached Biology News:Fetus suffers when mother lacks vitamin C 2Foetus suffers when mother lacks vitamin C 2Researchers sequence swine genome, discover associations that may advance animal and human health 2
(Date:6/1/2015)... Mich. , June 1, 2015  Neogen Corporation (NASDAQ: ... assets of Sterling Test House, a leading commercial food testing ... that the acquired laboratory will serve as a base for ... Sterling Test House was incorporated ... all of the food safety and water quality testing for ...
(Date:6/1/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") ... at the ERA-EDTA Congress in London, England ... a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in ... Disease (CKD); a Post-hoc Analysis of Patients from the ... Dr. Kam Kalantar-Zadeh , Professor and Chief, Division ...
(Date:6/1/2015)... 1, 2015  Berg, a biopharmaceutical company committed to ... clinical research from its trials using its cancer drug ... data on triple negative breast cancer, at the 51 ... Clinical Oncology (ASCO), May 29 – June 2 in ... 31510 is one of the first cancer drugs guided ...
(Date:6/1/2015)... , June 1, 2015 ... that it will be participating in the Jefferies 2015 ... on Tuesday, June 2, 2015. Jeff ... question and answer session at 10:00 a.m. ET (3:00 ... be available on the Presentations and Webcasts section of ...
Breaking Biology Technology:Neogen acquires India food safety company 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3
... industry will face many serious issues over the next ... rigors of engineering better biofuels and bioproducts. But few ... the 20,000 convention visitors at BIO '06. , ... ,A walk-through in Chicago's massive McCormick Place demonstrates just ...
... Standard Networks, Inc., a Madison software ... first three months of 2006, thanks largely to a ... file and message transfer management products. , ,Citing its ... numbers for MOVEit, but said Standard Network's overall revenues ...
... of complementary nanotechnology companies, Imago Scientific Instruments Corp. ... Tuesday that it has acquired the atom probe company Oxford ... was not disclosed, but the transaction makes Imago the world's ... Stultz. , ,The companies have a great deal in ...
Cached Biology Technology:My-oh, it's BIO! Where sales hype and science collide 2Imago acquires synergistic British firm 2
... carriers to suit the widest possible range ... science laboratory. Labware carriers can be placed ... is simple for the user, thanks to ... are correctly guided into position. This allows ...
... standard is a new tuning and calibration ... mass spectrometry. Accumix is a lyophilized ... coverage for both tuning and calibration of ... and Fourier transform mass spectrometers. Direct ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Biology Products: